JP2011182794A5 - - Google Patents

Download PDF

Info

Publication number
JP2011182794A5
JP2011182794A5 JP2011062697A JP2011062697A JP2011182794A5 JP 2011182794 A5 JP2011182794 A5 JP 2011182794A5 JP 2011062697 A JP2011062697 A JP 2011062697A JP 2011062697 A JP2011062697 A JP 2011062697A JP 2011182794 A5 JP2011182794 A5 JP 2011182794A5
Authority
JP
Japan
Prior art keywords
library
polypeptide
amino acid
polynucleotide
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011062697A
Other languages
English (en)
Japanese (ja)
Other versions
JP5358604B2 (ja
JP2011182794A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011182794A publication Critical patent/JP2011182794A/ja
Publication of JP2011182794A5 publication Critical patent/JP2011182794A5/ja
Application granted granted Critical
Publication of JP5358604B2 publication Critical patent/JP5358604B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011062697A 2003-06-27 2011-03-22 ルックスルー突然変異誘発 Expired - Lifetime JP5358604B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
US60/483,282 2003-06-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006517625A Division JP4791960B2 (ja) 2003-06-27 2004-06-25 ルックスルー突然変異誘発

Publications (3)

Publication Number Publication Date
JP2011182794A JP2011182794A (ja) 2011-09-22
JP2011182794A5 true JP2011182794A5 (enExample) 2012-02-09
JP5358604B2 JP5358604B2 (ja) 2013-12-04

Family

ID=33563915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006517625A Expired - Lifetime JP4791960B2 (ja) 2003-06-27 2004-06-25 ルックスルー突然変異誘発
JP2011062697A Expired - Lifetime JP5358604B2 (ja) 2003-06-27 2011-03-22 ルックスルー突然変異誘発

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006517625A Expired - Lifetime JP4791960B2 (ja) 2003-06-27 2004-06-25 ルックスルー突然変異誘発

Country Status (14)

Country Link
US (1) US20050136428A1 (enExample)
EP (1) EP1660655B1 (enExample)
JP (2) JP4791960B2 (enExample)
KR (1) KR20060034650A (enExample)
CN (1) CN1836041A (enExample)
AU (1) AU2004254352A1 (enExample)
BR (1) BRPI0412007A (enExample)
CA (1) CA2542192C (enExample)
ES (1) ES2609102T3 (enExample)
IL (1) IL172736A0 (enExample)
NO (1) NO20060108L (enExample)
RU (1) RU2005140664A (enExample)
WO (1) WO2005003345A2 (enExample)
ZA (1) ZA200510460B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
WO2006014498A2 (en) 2004-07-06 2006-02-09 Bioren, Inc. Universal antibody libraries
BRPI0511448A (pt) * 2004-07-06 2007-12-26 Bioren Inc anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
US9012369B2 (en) 2004-07-06 2015-04-21 Pfizer Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
WO2006094234A1 (en) * 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
EP1877441A2 (en) * 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
ES2402576T3 (es) * 2005-11-14 2013-05-06 Bioren, Inc. Ultrahumanización de anticuerpos por generación y selección de bibliotecas cohorte y blast de cdr maduras previstas
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
JP2009519983A (ja) 2005-12-20 2009-05-21 アラーナ・テラピューティクス・リミテッド 部分的な新世界ザル結合領域を有するキメラ抗体
EA017417B1 (ru) 2006-02-01 2012-12-28 Сефалон Астралия Пти Лтд. КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007112054A2 (en) * 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US8131480B2 (en) 2006-10-02 2012-03-06 Sea Lane Biotechnologies Llc Construction of diverse synthetic peptide and polypeptide libraries
US20080287320A1 (en) * 2006-10-04 2008-11-20 Codon Devices Libraries and their design and assembly
JP5594895B2 (ja) * 2007-06-06 2014-09-24 ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン タンパク質の能力の改良方法
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
EP2698380A1 (en) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
CN102625848A (zh) * 2009-07-17 2012-08-01 生物蛋白有限公司 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
US9753040B2 (en) 2010-12-01 2017-09-05 Mitsubishi Tanabe Pharma Corporation Polynucleotide construct capable of displaying fab in a cell-free translation system, and method for manufacturing and screening fab using same
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
WO2013158217A1 (en) * 2012-04-20 2013-10-24 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
DK2855674T4 (da) 2012-05-25 2022-11-21 Chr Hansen As Chymosinvarianter med forbedrede mælkekoagulerende egenskaber
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
KR101600899B1 (ko) * 2012-12-11 2016-03-09 주식회사 셀레믹스 초병렬적 핵산 합성법을 통한 dna 라이브러리의 동시 합성 방법
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
WO2015065987A1 (en) * 2013-11-01 2015-05-07 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
BR112016017502B1 (pt) 2014-02-26 2023-10-24 Chr. Hansen A/S Variantes de polipeptídeo de quimosina isoladas método para a produção das mesmas e método para a fabricação de um produto de alimentação humana ou animal
US10118967B2 (en) 2014-10-21 2018-11-06 Ablynx N.V. Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies
CN107849550B (zh) 2015-06-22 2021-09-03 科.汉森有限公司 具有改善的性质的凝乳酶变体
JP2018525996A (ja) 2015-08-31 2018-09-13 セーホーエル．ハンセン アクティーゼルスカブ 改良された特性を有するキモシンの変異体
WO2017119499A1 (en) * 2016-01-08 2017-07-13 Momotaro-Gene Inc. A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
CN109640677A (zh) 2016-05-19 2019-04-16 科·汉森有限公司 具有改善的凝乳特性的凝乳酶的变体
JP7395251B2 (ja) 2016-05-19 2023-12-11 セーホーエル．ハンセン アクティーゼルスカブ 改善された凝乳特性を有するキモシン変異体
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
MX2020006297A (es) 2017-12-15 2020-12-07 Aleta Biotherapeutics Inc Variantes de cd19.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527809B1 (en) * 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
WO1995023813A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning

Similar Documents

Publication Publication Date Title
JP2011182794A5 (enExample)
RU2005140664A (ru) Просматривающий мутагенез
Tchórzewski The acidic ribosomal P proteins
CA2572917A1 (en) Look-through mutagenesis for developing altered polypeptides with enhanced properties
JP2016512214A5 (enExample)
Fang et al. Dbf4 recruitment by forkhead transcription factors defines an upstream rate-limiting step in determining origin firing timing
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2020511672A5 (enExample)
RU2017134274A (ru) Связывающие tslp белки
HRP20180517T1 (hr) Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba
JP2012107017A5 (enExample)
JP2017518072A5 (enExample)
AR075882A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
HRP20160270T1 (hr) Monoklonska antitijela protiv glipikana-3
EP2821505A3 (en) Nucleotide-specific recognition sequences for designer tal effectors
RU2015140911A (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
JP2010500005A5 (enExample)
JP2013530929A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2015527368A5 (enExample)
HRP20161548T1 (hr) Protutijela za il-25
RU2019129917A (ru) Химерный антигенный рецептор
Leung et al. Molecular basis of BACH1/FANCJ recognition by TopBP1 in DNA replication checkpoint control
WO2006043972A8 (en) Chimeric protein
Vance et al. Resolution of two overlapping neutralizing B cell epitopes within a solvent exposed, immunodominant α-helix in ricin toxin's enzymatic subunit